$ImmunityBio (IBRX.US)$ The leading force in cancer innovati...
$ImmunityBio (IBRX.US)$ The leading force in cancer innovation is making real progress. Dr. Patrick Soon-Shiong and ImmunityBio are advancing Anktiva, a groundbreaking IL-15 superagonist immunotherapy that activates and proliferates the body's natural killer (NK) cells and memory T cells to precisely target and destroy tumors.
Instead of using harsh chemotherapy that harms healthy cells and weakens immunity, Anktiva restores and strengthens the immune system for targeted, longer-lasting attacks, offering hope for fewer side effects and better outcomes.
The visionary behind it, @DrPatrick, a surgeon, inventor, and the founder, executive chairman, and global chief scientific officer of ImmunityBio.
Anktiva won FDA approval in the US in 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. In January 2026, the Saudi FDA granted accelerated approval for:
• Anktiva + checkpoint inhibitor in metastatic non-small cell #LungCancer (the world’s first subcutaneous IL-15 treatment!)
• #Anktiva + BCG in BCG
unresponsive NMIBC
Moreover, robust trial data shows immune restoration, extended survival in difficult cases, and promising signals in the lungs, pancreas, glioblastoma, and more.
Sales are also surging. ImmunityBio reported preliminary net product revenue of approximately $113 million in 2025, a whopping 700% year-over-year increase!
Experts remain cautiously optimistic. More trials and approvals are needed, but this 'Immunotherapy 2.0' shift, which empowers the body's natural defenses, is becoming a game-changer for smarter, kinder cancer care.
As science advances, hope is building. The future of fighting #cancer looks brighter day by day.
Instead of using harsh chemotherapy that harms healthy cells and weakens immunity, Anktiva restores and strengthens the immune system for targeted, longer-lasting attacks, offering hope for fewer side effects and better outcomes.
The visionary behind it, @DrPatrick, a surgeon, inventor, and the founder, executive chairman, and global chief scientific officer of ImmunityBio.
Anktiva won FDA approval in the US in 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. In January 2026, the Saudi FDA granted accelerated approval for:
• Anktiva + checkpoint inhibitor in metastatic non-small cell #LungCancer (the world’s first subcutaneous IL-15 treatment!)
• #Anktiva + BCG in BCG
unresponsive NMIBC
Moreover, robust trial data shows immune restoration, extended survival in difficult cases, and promising signals in the lungs, pancreas, glioblastoma, and more.
Sales are also surging. ImmunityBio reported preliminary net product revenue of approximately $113 million in 2025, a whopping 700% year-over-year increase!
Experts remain cautiously optimistic. More trials and approvals are needed, but this 'Immunotherapy 2.0' shift, which empowers the body's natural defenses, is becoming a game-changer for smarter, kinder cancer care.
As science advances, hope is building. The future of fighting #cancer looks brighter day by day.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
